FilingSEC EDGAR8-K
Yarrow Bioscience Updates Clinical Development Progress via Investor Presentation
· SEC accepted
StageClinical Development
Filing content
The company released investor materials detailing the clinical development plan and key milestones for YB-101.
AI summary of the filing. Please also check the source.Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…